Cleared Traditional

K260250 - QCA 10 Electrocardiograph (QCARD-10)

Also marketed or referenced as:
QCA 10W Electrocardiograph (QCARD-10W)

K260250 is an FDA 510(k) clearance for QCA 10 Electrocardiograph (QCARD-10), manufactured by QT Medical, Inc.. The device is a Class 2 Cardiovascular device with product code DPS cleared through the Traditional 510(k) pathway after a 245-day FDA review.

K260250 · QT Medical, Inc. · Cardiovascular device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Sep 2026
Decision
245d
Days
Class 2
Risk

K260250 is an FDA 510(k) clearance for the QCA 10 Electrocardiograph (QCARD-10). Classified as Electrocardiograph (product code DPS), Class II - Special Controls.

Submitted by QT Medical, Inc. (Diamond Bar, US). The FDA issued a Cleared decision on September 29, 2026 after a review of 245 days - an extended review cycle.

This device falls under the Cardiovascular FDA review panel, regulated under 21 CFR 870.2340 - the FDA cardiovascular device oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Cardiovascular review framework, consistent with the majority of Class II 510(k) submissions.

View all QT Medical, Inc. devices

FDA 510(k) Submission Details - K260250

510(k) Number K260250 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received January 27, 2026
Decision Date September 29, 2026
Days to Decision 245 days
Submission Type Traditional
Review Panel Cardiovascular (CV)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
120d slower than avg
Panel avg: 125d · This submission: 245d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

DPS Device Classification - Class 2, Special Controls

Product Code DPS Electrocardiograph
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 870.2340
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Cardiovascular devices follow this clearance model.

Regulatory Peers - DPS Electrocardiograph

All 466
Devices cleared under the same product code (DPS) and FDA review panel - the closest regulatory comparables to K260250.
S-Patch CardioAI
K254255 · Wellysis Corp. · Sep 2026
SE-1202 Series Electrocardiograph (Model: SE-1202, SE-1202E)
K252463 · Edan Instruments, Inc. · Jul 2026
MAC 7 Resting ECG Analysis System
K251670 · Ge Medical Systems Information Technologies, Inc. · Jan 2026
AccurECG Analysis System (v2.0)
K252361 · Accurkardia, Inc. · Dec 2025
Withings BeamO (SCT02)
K252474 · Withings · Nov 2025
Cardiologs Holter Platform
K250569 · Philips France Commercial · Aug 2025